Heart disease isn't something that happens to other people -- to older men, to people who made different choices. It touches women of all ages and backgrounds, and because it so rarely looks the way we expect it to, it's still going largely unrecognized and, too often, untreated.
This guide is written in the hope that more women will see themselves in these pages -- will recognize a symptom, share these words with someone they love, or walk into their next doctor's appointment with a few more questions in hand.
When we think about the health threats women face, breast cancer is usually first in mind -- and rightly so. But heart disease quietly claims far more: approximately 300,000 women in the United States each year, compared to around 42,000 from breast cancer. All cancers combined account for roughly 278,000 female deaths annually.
This isn't said to frighten. Awareness -- real, informed awareness -- is where protection begins. And a significant portion of cardiovascular disease is preventable, detectable, and treatable, especially when women know what to look for.
Leading causes of death in U.S. women (relative scale)
When a heart attack doesn't look like one
We've all seen the movie version: a sudden, dramatic clutching of the chest, a collapse. And that version does happen. But for many women, a heart attack arrives much more quietly -- as fatigue that doesn't lift, or a nagging ache in the jaw, or a feeling that something is simply off. These subtler signals are just as real, and just as urgent. They're also far easier to dismiss.
Cardiologists describe this as "atypical" presentation, though in women it's actually quite common. Women are more likely than men to experience MINOCA (Myocardial Infarction with Non-Obstructive Coronary Arteries) and spontaneous coronary artery dissection -- conditions that don't produce the classic blockage pattern on standard imaging, which is why they're so frequently missed.
Women may experience chest pain -- but they are significantly more likely to present with these other warning signs, sometimes weeks before an event and often without any chest discomfort at all:
Why women face a different kind of risk
One of the most important things to understand about heart disease in women is that it genuinely operates differently -- biologically, diagnostically, and in treatment. The gap in outcomes between women and men isn't a mystery; it reflects decades of a healthcare system built around male physiology, now slowly being corrected.
The role of estrogen -- and what happens when it fades
For much of a woman's life, estrogen provides a quiet protective presence -- supporting healthy blood vessels, moderating inflammation, and maintaining a favorable lipid profile. After menopause, that protection diminishes, and cardiovascular risk rises more rapidly than most women expect. For women who experience menopause early -- before age 40 -- this shift comes sooner, and the elevated risk lasts longer.
Smaller vessels, different disease patterns
Women's coronary arteries are naturally smaller than men's, and women tend to develop coronary artery disease in a more diffuse pattern -- spread throughout the vessels rather than concentrated in distinct blockages. This makes certain standard procedures less effective and certain standard tests less revealing, which is part of why women's cardiac events are more likely to be initially missed.
Diagnostic and treatment gaps
Research consistently shows women wait longer before seeking care, are less likely to receive prompt diagnostic testing, and are more likely to have symptoms attributed to anxiety or GI causes. These gaps are not inevitable -- awareness is the first step toward closing them.
Risk factors unique to women
Standard cardiovascular risk calculators were developed largely from male data and often underestimate risk in women -- missing key factors like preeclampsia history, PCOS, autoimmune conditions, and menopausal metabolic shifts. These deserve to be part of every woman's cardiac risk conversation.
Hormone replacement therapy and the heart
Few topics in women's health have been more confusing than the relationship between hormone replacement therapy (HRT) and heart disease. What has emerged is what researchers call the "timing hypothesis" -- the idea that when HRT is started matters enormously, perhaps more than whether it is started at all.
How HRT is delivered also matters. Transdermal forms -- patches, gels, sprays -- carry lower blood clot risk than oral tablets. For women with an intact uterus, combined estrogen-progestogen therapy is standard, and the type of progestogen used can influence cardiovascular risk.
Major cardiology and menopause societies now recognize that for healthy women in the appropriate timing window, HRT benefits can outweigh the risks -- a decision that deserves an unhurried conversation with a physician who takes your history seriously.
Steps toward a heart-healthy life
Perhaps the most hopeful part of this conversation is about prevention. Up to 80% of cardiovascular events are thought to be preventable. Most of what protects the heart isn't dramatic -- it's consistent, accumulated care over time.
- ✓Know your numbersBlood pressure, cholesterol (LDL, HDL, and triglycerides), fasting glucose, and BMI all tell a story about cardiovascular health. Many of the most dangerous changes -- high blood pressure in particular -- happen without any symptoms at all.
- ✓Move, in whatever way works for youThe American Heart Association recommends at least 150 minutes of moderate aerobic activity weekly, but even modest, regular movement -- brisk walking, swimming, dancing -- significantly reduces cardiovascular risk. The best exercise is the one you'll actually do.
- ✓Nourish your body with intentionMediterranean and DASH dietary patterns have the strongest evidence for cardiovascular protection. The through-line: more vegetables, fruits, legumes, whole grains, and healthy fats; less processed food, sodium, and added sugar.
- ✓If you smoke, please consider quittingSmoking is one of the most powerful modifiable cardiovascular risk factors -- and the risk begins to fall within a year of stopping. There is never a point at which it's too late to benefit from quitting.
- ✓Take sleep and stress seriouslyChronic stress and poor sleep are increasingly recognized as real, independent cardiovascular risk factors. Cortisol affects blood pressure, inflammation, and blood sugar. Protecting sleep and building in genuine recovery aren't luxuries; for many women, they're medicine.
- ✓Be honest with your doctor about your full historyConditions in pregnancy -- preeclampsia, gestational hypertension, gestational diabetes, preterm delivery -- are not simply past events. They are ongoing cardiovascular signals that warrant continued monitoring.
- ✓Consider a coronary artery calcium score if you have risk factorsThis simple imaging test can detect subclinical cardiovascular disease -- arterial plaque building silently before any symptoms appear. It can be especially clarifying for women whose standard risk scores underestimate their true risk.
When the body turns against the heart: inflammation as a female-specific risk
For too long, cardiovascular risk in women has been measured by the same yardstick used for men. But several powerful risk factors -- rooted in immune function, reproductive history, and hormonal biology -- are unique to women, dramatically underappreciated, and directly tied to systemic inflammation.
Inflammation is not merely a symptom of disease -- it is a driver of it. Chronic, low-grade inflammation damages blood vessel linings, promotes plaque formation, accelerates arterial stiffening, and raises clot risk. For women, a cluster of conditions rooted in disordered immune response and reproductive physiology create a uniquely inflammatory cardiovascular environment that standard risk calculators routinely miss.
Autoimmune diseases affect women at roughly 3 to 1 over men. Conditions such as rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, inflammatory bowel disease, and Hashimoto's thyroiditis all involve chronic, systemic immune activation -- and all carry significantly elevated cardiovascular risk.
Women with lupus face a heart attack risk 5-10× higher than women without the disease; in younger women (aged 35-44), that risk rises to nearly 50 times that of age-matched peers. Women with rheumatoid arthritis have roughly double the cardiovascular risk -- comparable to type 2 diabetes.
Preeclampsia affects 5-8% of pregnancies worldwide and is now recognized as a major lifelong cardiovascular risk factor. Women who experience it face 2× the lifetime risk of heart disease and a 4× greater risk of hypertension later in life -- with impaired vascular function that can persist for decades after delivery.
Many women -- and their doctors -- view preeclampsia as a resolved pregnancy complication rather than an ongoing cardiovascular marker. This is a dangerous misconception. A history of preeclampsia should prompt lifelong cardiovascular surveillance.
Menopause before the age of 40 -- whether natural, surgical, or induced by chemotherapy -- is classified as premature ovarian insufficiency (POI). Women who experience it face up to 2× the risk of coronary artery disease. The earlier menopause occurs, the longer the body is deprived of estrogen's cardioprotective effects.
After estrogen withdrawal, inflammatory markers rise, LDL increases, HDL may fall, abdominal fat accumulates, and blood pressure tends to climb. For women with premature menopause, hormone replacement therapy initiated promptly is generally recommended as a cardiovascular protective measure.
Gestational diabetes mellitus resolves in most women after delivery -- but its cardiovascular consequences do not. Women who have had GDM face a 7× higher risk of developing type 2 diabetes later in life and a substantially elevated lifetime cardiovascular risk, independent of whether diabetes actually develops.
Despite this, the vast majority of women with GDM history receive no ongoing cardiovascular or metabolic surveillance. Screening for type 2 diabetes at 6-12 weeks postpartum and then every 1-3 years is recommended -- yet adherence rates remain critically low.
Diabetes is a cardiovascular risk factor in everyone -- but it is a more potent risk factor in women than in men. Women with type 2 diabetes have an ~40% greater relative risk of dying from heart disease compared to diabetic men, and face a 44% higher risk of coronary artery disease, even after controlling for other risk factors.
Women with diabetes also tend to be diagnosed later, have less well-controlled risk factors, and are less aggressively treated with cardiovascular protective medications such as statins and ACE inhibitors.
Targeted prevention: addressing inflammation directly
- hs-CRPThe strongest inflammatory predictor of cardiac events in women. A level above 2.0 mg/L is elevated; above 3.0 mg/L warrants action. Women with autoimmune disease, GDM history, or preeclampsia history should have this checked regularly.
- HbA1cReflects average blood glucose over 3 months. Essential for women post-GDM and those with autoimmune-related metabolic disruption. Goal for cardiovascular protection is generally below 7% in diabetic patients.
- Lp(a)A genetically determined, pro-inflammatory lipid particle that standard cholesterol panels miss. Elevated in 20% of the population. Should be measured at least once in high-risk women.
- Fasting insulin / HOMA-IRCan detect insulin resistance years before glucose rises to diabetic levels. Useful for monitoring women post-GDM who have normalized glucose but remain metabolically vulnerable.
- Coronary artery calcium (CAC)The single best tool for detecting subclinical cardiovascular disease in women with inflammatory risk factors. Can clarify statin candidacy in women whose standard risk scores underestimate their true risk.
Beyond statins: bempedoic acid and ezetimibe
Two non-statin therapies are rewriting what's possible for women who cannot tolerate statins, who need additional LDL reduction, or who carry elevated inflammatory burden that statins alone cannot fully address.
Up to 20% of women experience statin-related muscle symptoms and discontinue therapy, leaving their cardiovascular risk unaddressed. Others achieve guideline-recommended LDL levels on statins yet retain elevated hs-CRP that independently predicts future cardiac events. Bempedoic acid (Nexletol) and ezetimibe (Zetia) have emerged as powerful complements -- or alternatives -- with effects that extend beyond LDL reduction into inflammation modulation.
Works by inhibiting ATP-citrate lyase upstream of the statin pathway -- but is activated only in the liver, not in muscle tissue. This is why it does not cause the muscle side effects that drive statin discontinuation, making it transformative for statin-intolerant women.
The landmark CLEAR Outcomes trial demonstrated a 13% reduction in major adverse cardiovascular events in statin-intolerant patients -- the first randomized trial to show hard cardiovascular outcome benefit for a non-statin lipid-lowering drug in this population.
Works at the intestinal level, blocking the NPC1L1 transporter responsible for absorbing dietary and biliary cholesterol. Unlike bempedoic acid -- which targets hepatic synthesis -- ezetimibe targets absorption, giving it a completely complementary mechanism of action.
The IMPROVE-IT trial established that ezetimibe added to statin therapy reduced cardiovascular events -- the first trial to show that LDL reduction beyond statins translates to fewer events. It is exceptionally well tolerated, with no muscle-related side effects.
Bempedoic acid's hs-CRP reduction -- approximately 22-28% -- rivals that of high-intensity statins. The CLEAR Outcomes trial demonstrated that bempedoic acid reduced hs-CRP even in patients whose LDL did not fall substantially, suggesting the anti-inflammatory and lipid-lowering effects operate through partially separate pathways.
Bempedoic acid and ezetimibe are now available as a single fixed-dose combination pill -- brand name Nexlizet -- making compliance straightforward. The combination achieves ~38% LDL reduction with no muscle-related side effects, approaching moderate-intensity statin therapy.